Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenza Landi

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
Translational Lung Cancer Research|February 3, 2017
Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLCLorenza Landi, Federico Cappuzzo
Expert Review of Clinical Pharmacology|November 20, 2015
Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancerLorenza Landi, Federico Cappuzzo
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2018
<i>HER2</i> Deregulation in Lung Cancer: Right Time to Adopt an Orphan?Federico Cappuzzo, Lorenza Landi
Therapeutic Advances in Respiratory Disease|June 12, 2015
Experience with erlotinib in the treatment of non-small cell lung cancerLorenza Landi, Federico Cappuzzo
Expert Opinion on Pharmacotherapy|October 11, 2014
Management of NSCLC: focus on crizotinibLorenza Landi, Federico Cappuzzo
Annals of Translational Medicine|September 15, 2015
MET deregulation in breast cancerGabriele Minuti, Lorenza Landi
Translational Lung Cancer Research|March 26, 2015
Irreversible EGFR-TKIs: dreaming perfectionLorenza Landi, Federico Cappuzzo
Expert Review of Anticancer Therapy|October 19, 2013
HER2 and lung cancerLorenza Landi, Federico Cappuzzo
Translational Lung Cancer Research|January 25, 2021
How selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged diseaseLorenza Landi, Federico Cappuzzo
Expert Opinion on Pharmacotherapy|September 16, 2014
Pharmacotherapy targeting the EGFR oncogene in NSCLCLorenza Landi, Federico Cappuzzo
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
Translational Lung Cancer Research|February 3, 2017
Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLCLorenza Landi, Federico Cappuzzo
Expert Review of Clinical Pharmacology|November 20, 2015
Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancerLorenza Landi, Federico Cappuzzo
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2018
<i>HER2</i> Deregulation in Lung Cancer: Right Time to Adopt an Orphan?Federico Cappuzzo, Lorenza Landi
Therapeutic Advances in Respiratory Disease|June 12, 2015
Experience with erlotinib in the treatment of non-small cell lung cancerLorenza Landi, Federico Cappuzzo
Expert Opinion on Pharmacotherapy|October 11, 2014
Management of NSCLC: focus on crizotinibLorenza Landi, Federico Cappuzzo
Annals of Translational Medicine|September 15, 2015
MET deregulation in breast cancerGabriele Minuti, Lorenza Landi
Translational Lung Cancer Research|March 26, 2015
Irreversible EGFR-TKIs: dreaming perfectionLorenza Landi, Federico Cappuzzo
Expert Review of Anticancer Therapy|October 19, 2013
HER2 and lung cancerLorenza Landi, Federico Cappuzzo
Translational Lung Cancer Research|January 25, 2021
How selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged diseaseLorenza Landi, Federico Cappuzzo
Expert Opinion on Pharmacotherapy|September 16, 2014
Pharmacotherapy targeting the EGFR oncogene in NSCLCLorenza Landi, Federico Cappuzzo
Pageof 8